Shock therapy? giving testosterone to fight prostate cancer
NCT ID NCT06922318
Summary
This study is testing a two-step treatment for men whose prostate cancer has spread and stopped responding to standard hormone-blocking therapies. First, patients receive high-dose testosterone combined with an experimental drug called ZEN-3694. If the cancer progresses, they then switch to a different combination of enzalutamide (a standard prostate cancer drug) plus ZEN-3694. The goal is to see if this sequence can better control the cancer and delay its growth compared to past treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.